These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 27119710)

  • 1. [The cardiovascular outcome is critical].
    Stiefelhagen P
    MMW Fortschr Med; 2016 Feb; 158(3):68. PubMed ID: 27119710
    [No Abstract]   [Full Text] [Related]  

  • 2. [Empagliflozin: an oral antidiabetic with documented positive effect on cardiac mortality].
    Zechmann S
    Praxis (Bern 1994); 2016 Mar; 105(6):349-50. PubMed ID: 26980688
    [No Abstract]   [Full Text] [Related]  

  • 3. London buses: A cardiovascular outcome trial equivalent?
    Grant PJ
    Diab Vasc Dis Res; 2016 Nov; 13(6):382-383. PubMed ID: 27543327
    [No Abstract]   [Full Text] [Related]  

  • 4. The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects.
    Vettor R; Inzucchi SE; Fioretto P
    Diabetologia; 2017 Mar; 60(3):395-398. PubMed ID: 28074254
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of tofogliflozin 20 mg and ipragliflozin 50 mg used together with insulin glargine 300 U/mL using continuous glucose monitoring (CGM): A randomized crossover study.
    Takeishi S; Tsuboi H; Takekoshi S
    Endocr J; 2017 Oct; 64(10):995-1005. PubMed ID: 28824042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Empagliflozin improves cardiovascular prognosis].
    Stiefelhagen P
    MMW Fortschr Med; 2016 Mar; 158(5):70. PubMed ID: 26979229
    [No Abstract]   [Full Text] [Related]  

  • 7. Euglycemic diabetic ketoacidosis in type 2 diabetes with sodium glucose cotransporter 2 inhibitors.
    Wang AY; Hou SK; Li SJ; Kao WF
    Am J Emerg Med; 2017 Feb; 35(2):379.e5-379.e6. PubMed ID: 27614369
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus.
    Ilag LL; Deeg MA; Costigan T; Hollander P; Blevins TC; Edelman SV; Konrad RJ; Ortmann RA; Pollom RK; Huster WJ; Zielonka JS; Prince MJ
    Diabetes Obes Metab; 2016 Feb; 18(2):159-68. PubMed ID: 26434665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis.
    Scheen AJ
    Diabetes Metab; 2016 Apr; 42(2):71-6. PubMed ID: 26856453
    [No Abstract]   [Full Text] [Related]  

  • 10. The EMPA-REG study: What has it told us? A diabetologist's perspective.
    DeFronzo RA
    J Diabetes Complications; 2016; 30(1):1-2. PubMed ID: 26541076
    [No Abstract]   [Full Text] [Related]  

  • 11. [Acidosis without marked hyperglycemia : Euglycemic diabetic ketoacidosis associated with SGLT2-Inhibitors].
    Valek R; Von der Mark J
    Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):145-148. PubMed ID: 27221094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding EMPA-REG OUTCOME.
    Gilbert RE; Connelly KA
    Lancet Diabetes Endocrinol; 2015 Dec; 3(12):930-1. PubMed ID: 26590681
    [No Abstract]   [Full Text] [Related]  

  • 13. Understanding EMPA-REG OUTCOME.
    Ceriello A; Genovese S; Mannucci E; Gronda E
    Lancet Diabetes Endocrinol; 2015 Dec; 3(12):929-30. PubMed ID: 26590680
    [No Abstract]   [Full Text] [Related]  

  • 14. Understanding EMPA-REG OUTCOME.
    Muskiet MH; van Raalte DH; van Bommel EJ; Smits MM; Tonneijck L
    Lancet Diabetes Endocrinol; 2015 Dec; 3(12):928-9. PubMed ID: 26590679
    [No Abstract]   [Full Text] [Related]  

  • 15. In brief: Semglee - insulin glargine interchangeable with Lantus.
    Med Lett Drugs Ther; 2021 Oct; 63(1634):159-160. PubMed ID: 34550958
    [No Abstract]   [Full Text] [Related]  

  • 16. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Edwards JL
    N Engl J Med; 2016 Mar; 374(11):1093. PubMed ID: 26981943
    [No Abstract]   [Full Text] [Related]  

  • 17. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Rosenstein R; Hough A
    N Engl J Med; 2016 Mar; 374(11):1093-4. PubMed ID: 26981944
    [No Abstract]   [Full Text] [Related]  

  • 18. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Fischereder M; Schönermarck U
    N Engl J Med; 2016 Mar; 374(11):1092-3. PubMed ID: 26981942
    [No Abstract]   [Full Text] [Related]  

  • 19. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Sarafidis PA; Tsapas A
    N Engl J Med; 2016 Mar; 374(11):1092. PubMed ID: 26981941
    [No Abstract]   [Full Text] [Related]  

  • 20. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Zinman B; Lachin JM; Inzucchi SE
    N Engl J Med; 2016 Mar; 374(11):1094. PubMed ID: 26981940
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.